Browse SLC47A2

Summary
SymbolSLC47A2
Namesolute carrier family 47 (multidrug and toxin extrusion), member 2
Aliases FLJ31196; MATE2; MATE2-K; multidrug and toxin extrusion 2; MATE2-B; MATE2K; H+/organic cation antiporter; MA ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein Note=Localized at the brush border membranes of the proximal tubules.
Domain PF01554 MatE
Function

Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide, metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acyclovir, and ganciclovir. Responsible for the secretion of cationic drugs across the brush border membranes.

> Gene Ontology
 
Biological Process GO:0006855 drug transmembrane transport
GO:0015893 drug transport
GO:0042493 response to drug
GO:0046618 drug export
Molecular Function GO:0015077 monovalent inorganic cation transmembrane transporter activity
GO:0015078 hydrogen ion transmembrane transporter activity
GO:0015238 drug transmembrane transporter activity
GO:0015291 secondary active transmembrane transporter activity
GO:0015297 antiporter activity
GO:0015298 solute:cation antiporter activity
GO:0015299 solute:proton antiporter activity
GO:0015307 drug:proton antiporter activity
GO:0022804 active transmembrane transporter activity
GO:0090484 drug transporter activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-425471: Bile salt and organic anion SLC transporters
R-HSA-425407: SLC-mediated transmembrane transport
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-425366: Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
Summary
SymbolSLC47A2
Namesolute carrier family 47 (multidrug and toxin extrusion), member 2
Aliases FLJ31196; MATE2; MATE2-K; multidrug and toxin extrusion 2; MATE2-B; MATE2K; H+/organic cation antiporter; MA ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC47A2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSLC47A2
Namesolute carrier family 47 (multidrug and toxin extrusion), member 2
Aliases FLJ31196; MATE2; MATE2-K; multidrug and toxin extrusion 2; MATE2-B; MATE2K; H+/organic cation antiporter; MA ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC47A2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSLC47A2
Namesolute carrier family 47 (multidrug and toxin extrusion), member 2
Aliases FLJ31196; MATE2; MATE2-K; multidrug and toxin extrusion 2; MATE2-B; MATE2K; H+/organic cation antiporter; MA ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC47A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2790.291
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0090.987
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4950.323
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.010.0368
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8330.514
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.2370.443
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1350.844
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3260.797
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2190.861
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1390.797
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.4230.556
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5880.0992
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC47A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLC47A2
Namesolute carrier family 47 (multidrug and toxin extrusion), member 2
Aliases FLJ31196; MATE2; MATE2-K; multidrug and toxin extrusion 2; MATE2-B; MATE2K; H+/organic cation antiporter; MA ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC47A2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC47A2
Namesolute carrier family 47 (multidrug and toxin extrusion), member 2
Aliases FLJ31196; MATE2; MATE2-K; multidrug and toxin extrusion 2; MATE2-B; MATE2K; H+/organic cation antiporter; MA ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC47A2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC47A2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC47A2
Namesolute carrier family 47 (multidrug and toxin extrusion), member 2
Aliases FLJ31196; MATE2; MATE2-K; multidrug and toxin extrusion 2; MATE2-B; MATE2K; H+/organic cation antiporter; MA ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC47A2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC47A2
Namesolute carrier family 47 (multidrug and toxin extrusion), member 2
Aliases FLJ31196; MATE2; MATE2-K; multidrug and toxin extrusion 2; MATE2-B; MATE2K; H+/organic cation antiporter; MA ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC47A2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC47A2
Namesolute carrier family 47 (multidrug and toxin extrusion), member 2
Aliases FLJ31196; MATE2; MATE2-K; multidrug and toxin extrusion 2; MATE2-B; MATE2K; H+/organic cation antiporter; MA ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC47A2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC47A2
Namesolute carrier family 47 (multidrug and toxin extrusion), member 2
Aliases FLJ31196; MATE2; MATE2-K; multidrug and toxin extrusion 2; MATE2-B; MATE2K; H+/organic cation antiporter; MA ......
Chromosomal Location17p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC47A2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.